From BusinessWire CAMBRIDGE, Mass.–(BUSINESS WIRE)–Third Rock Ventures, LLC today announced the launch of Fulcrum Therapeutics, a company focused on unlocking gene control mechanisms to develop small molecule therapies. Fulcrum will… Read More »
New FSHD biotech launched with $55 million
Mouse grows a human muscle
With a little zap, transplanted human cells flourish in a mouse By June Kinoshita, FSH Society It’s like something out of Dr. Frankenstein’s underground laboratory, but a University of Maryland… Read More »
FSH Society Awards Grant to Establish Clinical Trial Research Network for FSHD
(PRWEB) JUNE 14, 2016 The FSH Society, a nonprofit, patient-driven organization that supports research and education for individuals with facioscapulohumeral muscular dystrophy (FSHD) and their families, today announced that it… Read More »
aTyr Pharma to advance Resolaris™ clinical programs
The San Diego-based biotech company, aTyr Pharma, Inc., released findings on March 30, 2016, from a Phase 1b/2 clinical trial of its experimental therapy Resolaris in adult facioscapulohumeral muscular dystrophy (FSHD) patients. While… Read More »
NIH funding for Facioscapulohumeral muscular dystrophy sets new record
We have some good news to share on National Institutes of Health funding for FSHD. As part of the FSH Society’s committee work in Washington, DC, we recently received FY2015… Read More »